ET-770 . Ecteinascidin 770, a Tetrahydroisoquinoline Alkaloid, Sensitizes Human Lung Cancer Cells To Anoikis .

The strategies for achieving anti-metastasis have received increased research interest and clinical attention. The anoikis-sensitizing effect of ecteinascidin 770 (ET-770) was investigated in the present study in non-small cell lung cancer cells.

 ET-770 isolated from Ecteinascidia thurstoni was tested for its anoikis-sensitizing effect on H23 and H460 human lung cancer cells by 2,3-b-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt (XTT) assay. The levels of proteins being involved in anoikis of cells were determined by western blot analysis.

Results :

ET-770 was shown to enhance anoikis response of human lung cancer H23 cells in a dose-dependent manner. The underlying mechanism was investigated and it was found that ET-770 sensitized the cells by activating the p53 protein, which in turn down-regulated anti-apoptotic myeloid cell leukemia sequence-1 (MCL1) and up-regulated BCL2-associated X protein (BAX) proteins. However, B-cell lymphoma-2 (BCL2) proteins were not significantly affected by ET-770. Further, the anoikis sensitization of ET-770 was observed in H460 lung cancer cells.

Conclusion :

The present results reveal for the first time that ET-770 can sensitize anoikis through the p53 pathway and further development of this compound for therapeutic use is warranted.


This paper is brought to you by the library at Arizona State University.

New Method for Detecting Tumours Using Nanoparticles . Resultados Satisfactorios del Proyecto Europeo NaNother , Liderado por Gaiker-IK4 con la Colaboración de PharmaMar entre otros .

The NANOTHER Project Terminated at the end of 2012. This has been a European research project led by Gaiker-IK4 with the double objective of developing Nanoparticles capable of locating of tumours and eliminating the pertinent cancer, releasing the pharmaceutical drug within the Nanoparticles in a controlled manner.

The ambitious research project, with a budget of almost 11 million euros —8 of which were funded by the European Commission — and in which some twenty bodies from throughout Europe have been taking part, came to a satisfactory end, the majority complying with the aims set out at the beginning.

  ...   Amongst the organisations involved in the project is Vicomtech-IK4, partner with Gaiker-IK4 in Alianza IK4, which has undertaken a primary role in the development of new software, besides CIC bioGUNE, Leitat and Pharmamar.